Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial
| Autor: | Pierre Michel, Laetitia Dahan, M.P. Galais, E. Boucher, J.H. Jacob, F. Di Fiore, H. Hamidou, S Prod'Homme, Marie-France Hellot, Bernard Paillot, Antoine Adenis, Xavier Mirabel, Jean-Luc Raoul |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2006 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty oesophageal cancer Esophageal Neoplasms medicine.medical_treatment Irinotecan Clinical Studies Antineoplastic Combined Chemotherapy Protocols Medicine Humans exclusive chemo-radiotherapy Survival rate induction chemotherapy Neoplasm Staging Chemotherapy Performance status business.industry Remission Induction Dose fractionation Induction chemotherapy Middle Aged Combined Modality Therapy Surgery Survival Rate Regimen Treatment Outcome Oncology Carcinoma Squamous Cell Camptothecin Female Dose Fractionation Radiation Cisplatin business Deglutition Disorders Chemoradiotherapy medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status3, caloric intake1,500 kcal day(-1) were included. Chemotherapy, with cisplatin 30 mg m(-2) and irinotecan 60 mg m(-2), was administered at days 1, 8, 22, 29, and concurrently with radiotherapy at days 43, 50, 64 and 71. Radiotherapy was delivered with 50 or 50.4 Gy in 25 fractions/5 weeks. Forty-three patients were included, 10 stage I, 19 stage II and 14 stage III. Mean age was 59.2 years (range 44-79). A total of 30 out of 43 (69.8%) patients underwent all planned treatment. During induction chemotherapy, 14 severe toxicities of grade 3 or 4 in 10 patients (23.3%) were reported with 57.1% due to haematoxicity. During chemoradiotherapy, 31 severe toxicities of grade 3 or 4 with 64.5% due to haematotoxicity were reported in 18 patients. One toxic death occurred (diarrhoea grade 4). The complete clinical response rate was 58.1% (95% CI: 43.4-72.8%). Overall survival rate at 1 and 2 years was 62.8%, (95% CI, 58.3-77.3%) and 27.9% (95% CI, 13.4-41.3%), respectively. In conclusion, cisplatin-irinotecan-radiotherapy is an active and well-tolerated regimen feasible in out-patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|